Novartis Ag (NVS) Change in Account Payables (2019 - 2026)
Novartis Ag's Change in Account Payables history spans 8 years, with the latest figure at -$53.0 million for Q1 2026.
- On a quarterly basis, Change in Account Payables rose 69.19% to -$53.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$183.0 million, a 76.98% increase, with the full-year FY2025 number at $102.0 million, up 134.34% from a year prior.
- Change in Account Payables hit -$53.0 million in Q1 2026 for Novartis Ag, down from $102.0 million in the prior quarter.
- Over the last five years, Change in Account Payables for NVS hit a ceiling of $102.0 million in Q4 2025 and a floor of -$409.0 million in Q1 2024.
- Historically, Change in Account Payables has averaged -$142.6 million across 5 years, with a median of -$115.0 million in 2022.
- Biggest five-year swings in Change in Account Payables: tumbled 8025.0% in 2022 and later surged 197.14% in 2025.
- Tracing NVS's Change in Account Payables over 5 years: stood at -$325.0 million in 2022, then rose by 28.92% to -$231.0 million in 2023, then skyrocketed by 54.55% to -$105.0 million in 2024, then surged by 197.14% to $102.0 million in 2025, then plummeted by 151.96% to -$53.0 million in 2026.
- Business Quant data shows Change in Account Payables for NVS at -$53.0 million in Q1 2026, $102.0 million in Q4 2025, and -$60.0 million in Q3 2025.